Phase I/II trial of latent membrane protein (LMP) - 2 immunization for the assessment of the natural history and the immunization-induced immunological response in patients at high risk for recurrence of anaplastic nasopharyngeal cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccines; Montanide ISA-51
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 04 Mar 2008 Biomarkers information updated
- 16 Apr 2007 The expected completion date for this trial is now 1 May 2006.
- 01 Nov 2005 New trial record.